ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Prognostic value of systemic inflammation-modified Patient-Generated Subjective Global Assessment in advanced cancers: A large-scale retrospective cohort study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA tight association between systemic inflammation and nutritional status has been established. We aim to evaluate the prognostic role of systemic inflammation-modified Patient-Generated Subjective Global Assessment (PG-SGA) criteria in advanced cancers.
methodIn this retrospective study, patients with advanced cancers were included from the West China Hospital between Nov 2019 and Sep 2023. Five systemic inflammatory indicators were selected, including the systemic inflammatory index (SII), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and advanced lung cancer inflammation index (ALI). Nutritional status was evaluated by the PG-SGA criteria. Kaplan-Meier curves, restricted cubic splines (RCS), and Cox regression analyses were used to estimate the effects of inflammation-modified PG-SGA index on the survival of cancer patients.
resultsIn total, there were 1,065 patients with advanced cancers included in our study. The ALI showed better predictive power in predicting the all-cause mortality of patients with advanced cancers when compared with other systemic inflammation indicators (4th quartile: hazard ratio (HR) = 0.38, 95% confidence interval (CI): 0.29, 0.50, P < 0.001). The ALI-modified PG-SGA index showed the best survival prediction value in patients with advanced cancers, with an AUC of ROC of 0.68 for 365-day mortality, 0.65 for 730-day mortality, and 0.64 for 1,300-day survival prediction, respectively. The C-index (0.626), calibration curves, and decision curve analysis validated the promising predictive accuracy of the PG-SGA/ALI index in predicting the all-cause mortality of patients with advanced cancers. The sensitive analyses also supported the consistent findings as we determined in the main regression.
conclusionsThe findings highlight that considering the host systemic inflammation status during the nutrition assessment would bring additional benefits to the survival prediction of advanced cancers. The PG-SGA/ALI index has moderate predictive value compared to the original PG-SGA criteria in the survival prediction of patients with advanced cancers. The PG-SGA/ALI index would be an optimal biomarker for precise survival prediction in cancer patients in clinical practice.
Indexed as
Identifiers
41081935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.